| General |
Apr 24, 2008
Theravance to Present at the Morgan Stanley Global Healthcare Unplugged Conference
|
Apr 15, 2008
Theravance to Webcast 2008 Annual Meeting of Stockholders on April 22, 2008
|
Mar 6, 2008
Theravance to Present at the Cowen and Company 28th Annual Health Care Conference
|
Mar 5, 2008
FDA Accepts for Review Theravance's Complete Response to Approvable Letter for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
|
Mar 3, 2008
Theravance Receives Additional Information Regarding FDA Cancellation of Advisory Committee Meeting
|
Feb 26, 2008
GlaxoSmithKline and Theravance Announce Expansion of the Horizon Programme with Start of Large Phase 2b Study of LABA in COPD Patients
|
Feb 23, 2008
FDA Cancels February 27, 2008 Advisory Committee Meeting to Review Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
|
Jan 24, 2008
Theravance to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
|
Jan 23, 2008
Theravance Announces Closing of $172.5 Million Public Offering of Convertible Subordinated Notes
|
Jan 17, 2008
Theravance Announces Pricing of Convertible Subordinated Notes Offering
|
Jan 15, 2008
Theravance to Present at the 13th Annual Stanford Group Healthcare Conference
|
Jan 15, 2008
Theravance Announces Proposed Offering of $150 Million of Convertible Subordinated Notes Due 2015
|
Jan 3, 2008
GlaxoSmithKline and Theravance Announce Start of Large Phase 2b ICS and LABA Studies for Asthma in the Horizon Programme
|
Dec 27, 2007
Theravance Receives Notice of Possible Telavancin Review by FDA Advisory Committee
|
Dec 19, 2007
Theravance Announces Appointment of Dr. Mathai Mammen as Head of Research
|
Dec 12, 2007
Theravance Announces Initiation of Phase 1 Clinical Study With Investigational Medicine For Respiratory Disease
|
Dec 5, 2007
Theravance Announces Positive Topline Results In Phase 3 Telavancin Hospital-Acquired Pneumonia Program
|
Oct 31, 2007
Theravance Announces Initiation of Phase 2 Clinical Program with its MABA Compound in COPD
|
Oct 30, 2007
Theravance to Present at Investor Conferences in November 2007
|
Oct 22, 2007
Theravance Receives FDA Approvable Letter for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
|
Oct 17, 2007
Theravance Reports Additional Data on Investigational Compound TD-5108 at 2007 American College of Gastroenterology Annual Scientific Meeting
|
Sep 18, 2007
Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC
|
Sep 13, 2007
Theravance Announces Expiration of Stockholder Put Period
|
Sep 6, 2007
Theravance Retains Full Ownership of Gastrointestinal Motility Dysfunction Program and TD-1792 Antibiotic
|
Aug 23, 2007
Theravance to Present at Investor Conferences in September 2007
|
Jul 31, 2007
Theravance Announces Appointment of Leonard M. Blum as Chief Commercial Officer
|
Jul 9, 2007
Theravance Announces Positive Results from Phase 2 Clinical Study with Investigational Antibiotic in Patients with Complicated Skin and Skin Structure Infections
|
Jul 5, 2007
Dr. Burton Malkiel Appointed to Theravance, Inc. Board of Directors
|
Jun 29, 2007
Theravance Announces that GlaxoSmithKline Will Not Exercise Call Right under Terms of Strategic Alliance to Acquire Additional Shares of Theravance Stock
|
Jun 25, 2007
Theravance Announces Positive Results from Phase 2 Clinical Study in Chronic Constipation with Investigational Compound TD-5108
|
Jun 20, 2007
Theravance Announces Enrollment of Last Patient in Phase 3 Hospital-Acquired Pneumonia Clinical Program with Investigational Antibiotic, Telavancin
|
May 30, 2007
Theravance Announces Acceptance of Telavancin MAA for the Treatment of Complicated Skin and Soft Tissue Infections in Europe
|
May 24, 2007
Theravance Announces Results From Preclinical Research and Phase 1 Clinical Studies With Investigational Gastrointestinal Motility Compound Presented at 2007 Digestive Disease Week
|
May 24, 2007
Theravance to Present at Investor Conferences in June 2007
|
May 1, 2007
Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Complicated Skin and Soft Tissue Infections in Europe
|
Apr 24, 2007
Theravance to Participate in Investor Conferences in May 2007
|
Apr 18, 2007
Theravance to Webcast 2007 Annual Meeting of Stockholders on April 25, 2007
|
Apr 9, 2007
Theravance to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
|
Apr 2, 2007
Theravance Announces Positive Results of Clinical Program in Beyond Advair Collaboration
|
Mar 1, 2007
Theravance to Present at Investor Conferences in March 2007
|
Feb 20, 2007
Theravance Announces FDA Acceptance of Telavancin NDA
|
Jan 26, 2007
Theravance to Host 2007 Investor R&D Day
|
Jan 26, 2007
Theravance to Present at the 2007 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
|
Jan 3, 2007
Theravance Initiates Phase 2 Clinical Program with Investigational Heterodimer Antibiotic
|
Jan 3, 2007
Theravance to Present at the 25th Annual JPMorgan Healthcare Conference
|
Dec 7, 2006
Theravance Submits U.S. NDA for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
|
Nov 20, 2006
Theravance to Present at the Piper Jaffray Health Care Conference
|
Nov 2, 2006
Theravance to Present at Investor Conferences in November 2006
|
Oct 10, 2006
Theravance Announces Additional Results From Successful Phase 3 Telavancin Complicated Skin and Skin Structure Program
|
Oct 9, 2006
Theravance Initiates Phase 2 Clinical Program In Gastrointestinal Motility Dysfunction
|
Oct 6, 2006
Theravance to Host Investor Conference Call Following Presentation at the Third International Symposium on Resistant Gram-Positive Infections
|
Sep 26, 2006
Telavancin Phase 3 ATLAS Data to Be Presented at Upcoming Conferences
|
Aug 29, 2006
Theravance Announces Upcoming Schedule of Investor Conferences in September 2006
|
Aug 22, 2006
Theravance Announces Positive Results in Phase 3 Telavancin Complicated Skin and Skin Structure Infection Program
|
Jul 18, 2006
Theravance and Astellas Add Japan to Collaboration on Telavancin, Investigational Antibiotic for Serious Infections
|
Jun 12, 2006
Theravance Announces Second Compound's Entry into Phase 2b Clinical Program in Beyond Advair Collaboration with GlaxoSmithKline
|
May 31, 2006
Theravance to Present at the Pacific Growth Equities Life Sciences Growth Conference
|
May 17, 2006
Theravance to Present at the Bear Stearns Biotech Boston Confab
|
May 16, 2006
Theravance Announces Enrollment of Last Patient in Phase 3 Complicated Skin and Skin Structure Infections Clinical Program with Investigational Antibiotic, Telavancin
|
May 2, 2006
Theravance to Present at the Bank of America Health Care Conference 2006
|
Apr 21, 2006
Theravance to Present at the Morgan Stanley 2006 Global Healthcare Unplugged Conference
|
Apr 20, 2006
Theravance Announces Initiation of Phase 2b Clinical Program with Investigational Long-Acting Beta Agonist in Beyond Advair Collaboration
|
Apr 19, 2006
Theravance To Webcast 2006 Annual Meeting of Stockholders on April 26, 2006
|
Mar 30, 2006
Theravance to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
|
Mar 15, 2006
Theravance to Present at the Bear Biotech West Coast Confab
|
Feb 28, 2006
Theravance to Present at the Cowen & Co. 26th Annual Health Care Conference
|
Feb 28, 2006
Theravance to Present at the Lehman Brothers Ninth Annual Global Healthcare Conference
|
Feb 17, 2006
Theravance to Present at the Citigroup 2006 Healthcare Conference
|
Feb 3, 2006
Theravance to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
|
Feb 1, 2006
Theravance Announces Pricing of Common Stock Offering
|
Jan 30, 2006
Theravance Announces Proposed Public Offering of Common Stock
|
Jan 10, 2006
Theravance Updates Guidance for Initiation of Phase 2b in the LABA Collaboration
|
Jan 3, 2006
Theravance to Present at the 24th Annual JPMorgan Healthcare Conference
|
Dec 22, 2005
Theravance Announces Results from Phase 1 Clinical Studies With TD-2749, an Investigational Medicine for Gastrointestinal Motility Dysfunction
|
Dec 21, 2005
Theravance Reports Additional Results From Clinical Studies With Investigational Antibiotic Telavancin
|
Dec 21, 2005
Theravance Reports Results From Pre-clinical Studies With Investigational Antibiotic Telavancin
|
Dec 12, 2005
Dr. Eve E. Slater Appointed to Theravance, Inc. Board of Directors
|
Dec 5, 2005
Theravance and Astellas Finalize Collaboration on Telavancin, Investigational Antibiotic for Serious Infections
|
Nov 9, 2005
Theravance to Present at the Credit Suisse First Boston Health Care Conference
|
Nov 7, 2005
Theravance and Astellas to Collaborate on Telavancin, Investigational Antibiotic for Serious Infections
|
Oct 5, 2005
Theravance to Present at BIO InvestorForum
|
Sep 14, 2005
Theravance to Present at Global Pharmaceutical, Biotech & Medtech Conference
|
Aug 30, 2005
Theravance to Present at Thomas Weisel Partners' Healthcare Conference 2005
|
Jun 28, 2005
Theravance To Webcast Annual Stockholders' Meeting on June 30, 2005
|
Jun 27, 2005
Theravance Announces Results of Phase 2 Clinical Study Showing 24-Hour Bronchodilation With Investigational Medicine
|
Jun 13, 2005
Theravance Announces Initiation of Phase 1 Clinical Study with Investigational Medicine for Respiratory Disease
|
Jun 6, 2005
Theravance to Present at Thomas Weisel Partners Growth Forum 7.0
|
Apr 7, 2005
Theravance Announces Results From Clinical And Pre-Clinical Studies With Investigational Antibiotic Telavancin
|
Mar 28, 2005
Theravance Announces Fast Track Designation for Investigational Antibiotic Telavancin
|
Mar 25, 2005
Theravance to Present at Lehman Brothers Eighth Annual Global Healthcare Conference
|
Mar 21, 2005
Theravance Announces GlaxoSmithKline License of Third Respiratory Program
|
Mar 1, 2005
Theravance Announces Publication of Telavancin's Multifunctional Mechanism of Action
|
Feb 17, 2005
Theravance to Present and Participate in Expert Panel on 'New Antibiotics Against New and Old Threats' at BIO CEO and Investor Conference
|
Feb 4, 2005
Theravance To Present At Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
|
Feb 3, 2005
Theravance Names Michael W. Aguiar Chief Financial Officer
|
Jan 28, 2005
Theravance To Host Investor Presentation
|
Jan 26, 2005
Theravance Announces Initiation of Phase 3 Clinical Studies in Hospital Acquired Pneumonia with Investigational Antibiotic Telavancin
|
Jan 10, 2005
Theravance to Webcast JPMorgan Healthcare
|
Jan 7, 2005
Theravance to Present at the JP Morgan Healthcare Conference
|
Jan 4, 2005
Theravance Announces Initiation of Phase 1 Clinical Study with Investigational Medicine for Gastrointestinal Motility Dysfunction
|
| Financial Results |
Apr 21, 2008
Theravance Reports First Quarter 2008 Financial Results
|
Apr 14, 2008
Theravance to Report First Quarter 2008 Financial Results on April 21, 2008
|
Feb 14, 2008
Theravance Reports Fourth Quarter and Full Year 2007 Results
|
Jan 31, 2008
Theravance to Report Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
|
Oct 25, 2007
Theravance Reports Third Quarter 2007 Financial Results
|
Oct 11, 2007
Theravance to Report Third Quarter 2007 Financial Results on October 25, 2007
|
Jul 26, 2007
Theravance Reports Second Quarter 2007 Financial Results
|
Jul 12, 2007
Theravance to Report Second Quarter 2007 Financial Results on July 26, 2007
|
Apr 26, 2007
Theravance Reports First Quarter 2007 Financial Results
|
Apr 12, 2007
Theravance to Report First Quarter 2007 Financial Results on April 26, 2007
|
Feb 8, 2007
Theravance Reports Fourth Quarter and Full Year 2006 Results
|
Jan 25, 2007
Theravance to Report Fourth Quarter and Full Year 2006 Financial Results on February 8, 2007
|
Oct 26, 2006
Theravance Reports Third Quarter 2006 Results
|
Oct 12, 2006
Theravance to Report Third Quarter 2006 Financial Results on October 26, 2006
|
Jul 27, 2006
Theravance Reports Second Quarter 2006 Results
|
Jul 13, 2006
Theravance To Report Second Quarter 2006 Financial Results on July 27, 2006
|
Apr 27, 2006
Theravance Reports First Quarter 2006 Financial Results
|
Apr 13, 2006
Theravance To Report First Quarter 2006 Financial Results on April 27, 2006
|
Feb 9, 2006
Theravance Reports Fourth Quarter And Full Year 2005 Financial Results
|
Jan 31, 2006
Theravance to Report Fourth Quarter and Full Year 2005 Financial Results on February 9, 2006
|
Oct 27, 2005
Theravance Reports Third Quarter 2005 Financial Results
|
Oct 13, 2005
Theravance To Report Third Quarter 2005 Financial Results on October 27, 2005
|
Jul 27, 2005
Theravance Reports Second Quarter 2005 Financial Results
|
Jul 15, 2005
Theravance To Report Second Quarter 2005 Financial Results on July 27, 2005
|
May 4, 2005
Theravance Reports First Quarter 2005 Financial Results
|
Apr 18, 2005
Theravance To Report First Quarter 2005 Financial Results on May 4, 2005
|
Feb 16, 2005
Theravance Reports Fourth Quarter And Full Year 2004 Financial Results
|
Jan 31, 2005
Theravance To Report Fourth Quarter 2004 Financial Results
|